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Abstract
Purpose The maintenance of an obtained lower weight
level is often found to be difﬁcult. The aim of this study
was to determine weight maintenance after an initial
weight loss by consumption of a meal replacement with a
vegetable-oil emulsion associated with prolonged satiety.
Methods After a 6-week weight loss period with very low
calorie diet (VLCD), subjects with[5% body weight (BW)
loss were randomized to a 12-week weight maintenance
follow-up period, comparing a partial meal replacement
diet containing a vegetable-oil emulsion (test) or dairy fat
(control). Anthropometric data and safety variables were
collected at baseline and after 4, 8 and 12 weeks.
Results A signiﬁcant weight loss was observed during
the 12-week weight maintenance diet in the test and
control group, respectively; 1.0 ± 2.1 kg (p\0.05) versus
1.3 ± 2.1 kg (p\0.05) with no signiﬁcant difference
between the groups. Body fat mass (BFM) decreased sig-
niﬁcantly (p\0.05) in the test group (-1.7%) compared
to the control group (-0.8%).
Conclusions Addition of a vegetable-oil emulsion to a
meal replacement weight maintenance program after an
initial weight loss using VLCD was associated with
decreased BFM by 0.9% without any change in BW
between the two groups.
Keywords Weight maintenance  VLCD 
Body fat mass  BFM  Body weight  Fat emulsion
Background
The prevalence of overweight and obesity is growing and
has been classiﬁed as an epidemic according to the WHO
(World Health Organization) [1]. Overweight/obesity is not
only a health burden in itself but also linked to many
metabolic diseases. Even a moderate weight loss of 5–10%,
if sustained, has beneﬁcial effects by reducing the inci-
dence of diabetes [2]. Such a weight loss can be achieved
within 6–8 weeks by using a very low calorie diet (VLCD)
[3]; however, the obtained lower weight is difﬁcult to
sustain over a longer time [4]. A greater initial weight loss,
induced without changes of lifestyle, has been shown to
improve long-term weight maintenance [5, 6] provided that
it is followed by supporting integrated weight maintenance
programs [7]. One therapeutic option, which can be
included in a maintenance program, is the use of a meal
replacement therapy after an initial weight loss. When meal
replacement therapies have been compared with traditional
energy restriction diets, a greater long-term weight loss has
been obtained with a partial (one) meal replacement regi-
men (PMR) [8]. However, compliance to the altered food
intake behavior is one of the major challenges in the ﬁeld
of weight maintenance; hence ingredients, which affect
satiety, could play a role by increasing compliance to a
weight maintenance program. Satiety feelings appear as a
response to ingested food, and there is good evidence
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tems referred to as ileal brake, which sense the presence of
nutrients in the gastrointestinal system in order to regulate
appetite [9–11]. Speciﬁcally, lipids when present in the
small intestine can stimulate strong feedback signals
associated with satiety, slowing of gastrointestinal transit
and release of satiety hormones [11, 12].
An ingredient, which has been shown to increase satiety,
is a vegetable-oil emulsion (Fabuless
TM) of palm and oat
oils in water. Previous short-term studies, all randomized,
controlled, single blind or double blind trials, have dem-
onstrated that administration of this vegetable-oil emulsion
has reduced subsequent food intake and induced satiety
[13–15], although two studies [16, 17] did not show any
effect of this fat emulsion on food intake. The inconsis-
tency of the results may, at least in part, be attributed to
heterogeneity in statistical and methodological approaches.
Further investigations to clarify the mechanism(s) behind
this vegetable-oil emulsion have demonstrated a delayed
transit time of a subsequent meal [18] and higher amount of
lipids in the intestine compared to control treatment [19].
These ﬁndings may well be associated with ileal brake,
which has been suggested as a possible mechanism behind
the effect in the short-term studies. During a previous long-
term study in overweight women, consumption of this
vegetable-oil emulsion in a yoghurt preparation improved
maintenance of body weight (BW) after an initial weight
loss induced by VLCD [20]. Reduced hunger feelings most
likely associated with the raised levels of satiety hormones
and increased resting energy expenditure leading to a rel-
ative decrease in BFM were suggested as mechanisms
explaining these ﬁndings [20].
The aim of this study was to investigate whether a PMR
weight maintenance approach using this vegetable-oil
emulsion may have an effect on BW and body composition
after an initial weight loss with VLCD. A secondary
objective was to investigate the safety relative to the effects
on resting energy expenditure.
Methods
Subjects
Seventy-nine female subjects aged 18–60 years with a
body mass index (BMI) of 26–31 kg/m
2 were screened.
Subjects with a history of cardiovascular, mental or other
serious diseases, or a systolic blood pressure C160 mm Hg
or a diastolic blood pressure C105 mm Hg, alcohol or
substance abuse, history of soy bean or milk allergy and
consumption of drugs affecting BW were not eligible to
enter the study. For entering the randomized phase of the
12-week weight maintenance phase, subjects should reduce
BW with at least 5% at the end of a six-week VLCD
period.
The local ethics committee at the Faculty of Medicine at
Uppsala University approved the study. Signed informed
consent was obtained from all participants.
Study design
The study had a randomized, controlled, double-blind,
parallel design and consisted of two phases; an initial
weight reduction period of 6 weeks using a calorie-
restricted diet, VLCD, followed by a random allocation to
a test or control weight maintenance treatment period of
12 weeks. During the ﬁrst 2 weeks of the weight reduc-
tion phase, the subjects consumed 5 units of Nutrilette
Intensive daily (557 kcal Energy% C/F/P 37/21/42;
Nutrilett Intensive chocolate, Axellus AB, Sweden), which
gives 100% of RDI of minerals and vitamins. Nutrilette
Intensive is a commercial product on the Swedish market
and was purchased at a supermarket for this study. One
unit of Nutrilette Intensive was added to 200 mL of cold
water and immediately shaked for 10–15 s before con-
sumption. The subjects were also strictly instructed to
drink a minimum of 2.5 L of non-caloric beverage/day.
No other food or drink items were allowed. During the
remaining 4 weeks of the weight reduction phase, the
subjects ingested ad lib a regular breakfast and 4 units of
Nutrilette Intensive daily (111 kcal/unit, in total 444 kcal/
day). All subjects received information and advice about a
healthy breakfast meal. Subjects with a BW loss of at
least 5% were randomized into the weight maintenance
intervention phase of 12 weeks, during which the partic-
ipants resumed to their habitual eating patterns except for
the lunch, which was replaced by Nutrilette Intensive
meal (111 kcal) mixed with test emulsion or control. The
subject mixed one unit of Nutrilette Intensive with
200 mL of cold water as described previously and added
the test or control emulsion to the mixture during stirring.
The subjects were requested not to change their exercise
habits during the study.
Products
The 12.5 g test vegetable-oil emulsion (Fabuless
TM, DSM
Food specialties Delft, The Netherlands) contained 5.2 g
fat and 7.3 g water (46 kcal/day), while the 13.8 g of
cream, which was used as control, contained 5.2 g fat,
0.4 g protein, 0.3 g carbohydrate and 7.9 g water (49 kcal/
day). The products were dispensed in a double-blind
manner in ready to use portion packs for daily use. The
subjects reported consumption in a diary, which together
with the returned unused portion packs constituted the
basis for calculation of the compliance.
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123Measurements
Body weight (BW), sagittal abdominal diameter SAG, waist
and hip circumferences, skinfolds, heart rate and blood
pressure measurements were performed every second week
during the weight reduction phase and every fourth week
duringtheweightmaintenanceperiod.Thesameequipments
were used, and the same nurse performed the measurements
duringthestudyinordertoincreasethereproducibilityofthe
measurements, and in addition, the weight loss phase was
used as training of the subjects to become more comfortable
with measurements (data not shown).
Anthropometric
BW was measured using a digital balance accurate (CL-
300 BMI, Carl Liden, Gothenburg, Sweden) with subjects
wearing indoor cloths without shoes, wallet and keys.
Height was measured using a wall-mounted stadiometer at
the screening visit. Body mass index (BMI) was calculated
by dividing the BW (kg) by body height squared (m
2).
BFM and body muscle mass (BMM) were estimated by
skinfold measurements at four different locations on the
body: biceps, triceps, subscapular and suprailiac [21] and
carried out with a Harpenden caliper (Baty Int, West
Sussex, UK). The waist and hip circumferences were
measured between the iliac crest and the lowest part of the
lowest rib with the subjects in underwear in a standing
position. The subject was asked to exhale before the waist
circumference was performed. Sagittal abdominal diameter
(SAG) was measured with the subject laying on the back,
on a ﬂat and hard surface and deﬁned as the distance
between the surface and the highest point of the abdomen.
Blood pressure and pulse rate
Blood pressure and pulse rate were measured oscillomet-
rically (Omron M4-I, Omron Healthcare Europe B.V.,
Hoofddorp, The Netherlands) in the sitting position in the
right arm after a resting period of 3–5 min. A total of three
measurements with 2–5 min intervals were performed, and
the average of these measurements was calculated.
Body temperature
Body temperature was measured rectal by Terumo Elec-
tronic Fever Thermometer C402. The same thermometer
was used during the study.
Biochemical analyses
The subjects arrived at the study site after 12-h fasting.
Plasma and serum were obtained from blood samples via
venapuncture in the forearm for determination of hemo-
globin (Hb), glycosylated hemoglobin (HbA1c), alanine
aminotransferase (ALAT), triglycerides (TG), apolipopro-
tein A1 (ApoA1), apolipoprotein B (ApoB), gamma glut-
amyl transpeptidase (GGT), glucose (Glc), potassium (K),
sodium (Na), creatinine (Crea) and thyroid-stimulating
hormone (TSH). Urine dipstick analyses were carried out
as well. The biochemical analyses were performed before
the weight reduction phase, at baseline and after 12-week
weight maintenance treatment and carried out at the
Department of Clinical Chemistry, University Hospital,
Uppsala.
Adverse events
All adverse events deﬁned as any untoward occurrence in a
subject in the study, whether considered related to the
study treatment, were collected, documented and reported.
An adverse event form was ﬁlled in for each separate
adverse event.
Power calculation
Study group sizes were determined to detect a difference of
1.8 kg between test and control groups; with a power of
80% and a standard deviation (SD) of 2.0 and a type I error
of 5%, a sample size of 21 subjects in each group was
required, with a total of 42 subjects (Sample power, SPSS,
Chicago, Illinois, USA). Drop out rate for the initial weight
loss period as well as for the intervention period was set at
30% leading to a total number of 60 subjects to include in
the weight reduction period (Fig. 1).
Statistics
Data are presented as mean and standard deviation (SD) or
95% conﬁdence intervals (CI). Differences between test
treatment and control treatment groups for baseline char-
acteristics were analyzed with an unpaired t-test using
SPSS version 15.0 (Chicago, Illinois, USA). The study of
data evolution throughout the follow-up was performed
with the analysis of variance for repeated measurements
(ANOVA). For inferring a treatment effect from the dif-
ference between test group and control group on a quan-
titative outcome measured before and after treatment,
analysis of covariance (ANCOVA) of the outcome with the
baseline as covariate was performed (Univariate Mixed
Effect Model Approach). Statistical analysis of variance as
well as analysis of covariance was performed using SAS
software (SAS Institute, Cary, NC, USA). p values\0.05
were considered statistically signiﬁcant. Subjects were
included in the statistical evaluation if compliance to
treatment was at least 70%.
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123Results
Of 79 screened subjects, 54 were found eligible to the
weight reduction phase, after which 46 subjects were ran-
domized into the weight maintenance intervention phase
based on the body weight loss. One subject withdrew for
personal reasons; thus, 45 subjects completed the study. Of
these 45 subjects who completed the entire study, two
subjects were excluded from the statistical analysis due to
violation of the study protocol and poor compliance,
respectively. The relative compliance was 90.8 ± 7.8 for
the test treatment and 91.4 ± 8.5% for the control treat-
ment. The two excluded subjects had a compliance of 66.7
and 64.3%, respectively, hence well below the level in the
protocol. Thus, 43 subjects were included in the statistical
calculations (Fig. 1).
Initial characteristics
Table 1 shows the characteristics of the study participants
at the start of the weight reduction phase, and the two
groups did not differ in characteristics. As a consequence
of the restricted energy intake, BW was signiﬁcantly
lowered at the end of the weight reduction phase compared
to the initial values. The test treatment group decreased the
mean body weight by 6.7 ± 1.5 kg, and the corresponding
weight loss for the control group was 7.5 ± 1.7 kg with no
signiﬁcant difference between the two groups.
Characteristics at randomization
Table 2 shows the characteristics of the study participants
during weight maintenance phase. At baseline, after ran-
domization, systolic and diastolic blood pressures were
found to be signiﬁcantly higher in the test treatment group
(121/80 mm Hg) when compared to the control group (116/
75 mm Hg) (p\0.05). No other signiﬁcant differences
were observed between the two groups.
Treatment effects during the weight maintenance
After 12 weeks of weight maintenance by partial meal
replacement regimen (PMR), body weight was signiﬁ-
cantly reduced in both groups (test group: 1.0 ± 2.1 kg,
p\0.05), (control group: 1.3 ± 2.1 kg, p\0.05) with no
difference between the groups. BFM was signiﬁcantly
54 subjects enrolled to run-in 
25 persons found ineligible 
8 subjects withdraw during run-in 
46 subjects randomised 
79 potentially eligible subjects screened 
22 subjects were 
included in whole/parts 
of the efficacy analyses 
21 subjects were 
included in whole/parts 
of the efficacy analyses 
1 subject 
withdrew 
0 subject 
withdrew
23 subjects 
Test
23 subjects 
Control 
0 subject low 
compliance 
2 subjects low 
compliance
Fig. 1 Overview and
disposition of subjects
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123reduced in the test group from baseline to 12-week follow-
up (p\0.05) (Fig. 2), whereas the reduction in the control
group was not signiﬁcant. A signiﬁcant over time differ-
ence (analysis of variance (ANOVA) two-factor repeated
measures) was obtained between the treatments (p\0.01).
Furthermore, correction for baseline measurement did not
alter the results (difference between test-control = 0.57,
p\0.01, repeated measurement ANCOVA). Furthermore,
waist circumference decreased by 1.2 cm in the test group
(p\0.05, t-student), while the decrease by 0.6 cm in the
control group was not signiﬁcant, with no signiﬁcant dif-
ference between the two treatment regimens. The muscle
mass increased by 3.6% (p\0.05), from 39.2 to 40.6%, in
the test treatment group and by 2.8% (p\0.05), from 39.8
to 40.9%, in the control group, however, with no statistical
difference between the groups. No other signiﬁcant inter-
group differences for other parameters listed in Table 2
were observed. There were no signiﬁcant group–time
interactions (data not shown). The reduction of BFM
showed a nadir with both treatment regimens at week 8, the
level tended to stabilize, which could be noticed on the
body weight reduction (Fig. 2).
Safety and adverse effects
The safety and metabolic parameters (data not shown) as
well as blood pressure, pulse rate, and body temperature
(data not shown) were within the normal range and
unaltered during the study. No intra- or intergroup changes
were observed regarding the metabolic and lipid variables.
The ALAT levels, which increase in both groups during the
weight reduction phase, were normalized during the 12-
week weight maintenance phase. The frequency of adverse
events collected during the different phases of the study
showed no differences between treatments. Thirteen
adverse events were reported in each treatment group. The
incidence of adverse events by class is summarized in
Table 3. In the test group, three adverse events were
reported as possibly related whereof all were resolved at
the end of the study. In the control group, two adverse
events were reported as possibly related, and both of them
were resolved at the end of the study. One of the subjects
in the control group noted two adverse events. Seven and
six subjects, respectively, in the test and control group,
reported changes in background medication during the
study; however, the results observed in this study remained
when the participants reporting changes in background
medication were excluded from the statistical calculation.
Discussion
Our study demonstrated that a 12-week partial meal
replacement with a vegetable-oil emulsion regimen per-
formed after an initial body weight loss with VLCD sig-
niﬁcantly lowered the BFM when compared to a control
group. This alteration was independent of baseline values.
However, regarding changes in BW, there was no differ-
ence between the groups treated with the vegetable-oil
emulsion compared to control. Since the anthropometric
measures are subjective, steps were taken to ensure that
these measurements were reproducible by using the same
nurse and equipments as well as allow subjects to get
accustomed to the procedure.
There were no signiﬁcant differences between the test
and control groups on waist circumference and SAG;
nevertheless, a signiﬁcant decrease in waist circumference
was obtained from baseline in the test group, which might
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Fig. 2 Change in body fat mass (% of body weight for the test and
control groups during treatment). Values are means. p\0.05 over
time difference from baseline compared to week 12 (repeated
measurement ANOVA)
Table 3 Incidence of adverse events by class
AE classiﬁcation Control* Test*
Pain and ache 0 1
Infections 5 5
Gastrointestinal disorders 5 5
Asthma and allergy 1 1
Accidents 0 1
Other 2 0
* Number of adverse events reported. One subject noted 2 adverse
events
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123support the change in BFM. Waist circumference has been
shown to predict BFM [22] and obesity-related metabolic
[23] and cardiovascular risk factors [24]. In a study, Ross
et al. [25] showed that a reduction in waist circumference
by 1 cm is equivalent to a loss of abdominal fat of 0.33 kg.
If applied to our study, the subjects in the test group
treatment would have lost 0.40 kg of abdominal fat versus
0.20 kg in the control group during the follow-up phase.
Given the importance of abdominal fat in the pathogenesis
of the metabolic syndrome [26], it could be speculated that
the observed reduction in body fat mass is an important
ﬁnding with respect to its impact on health.
In our study, overweight subjects were recruited, but by
reducing body weight, BMI decreased accordingly leading
to a BMI close to normal at the end of the study with a
major reduction during the initial weight loss. A BMI close
to the normal range during the treatment period could
explain the relatively small effect on BW, BFM and waist
circumference and lack of signiﬁcant effect on SAG. In
contrast to the BFM, which decreased over time and
between treatments, the BW was only slightly reduced. The
BMM increased 1.4% at the 12-week follow-up compared
to baseline and not over time between treatments. Hence,
this reciprocal relationship between BMM and BFM might
help to explain the limited decrease in total BW. The wide
interindividual variations might also help to explain why
changes in BW did not reach statistical signiﬁcance.
There is a growing body of literature that supports the
effectiveness of meal replacement programs [8, 27, 28].
Subjects using these strategies were shown to improve
behavioral compliance, increase their nutritional knowl-
edge and had more regular meals and snacked less [28].
Accordingly, VLCD and PMR programs have beneﬁcial
effect on parameters linked to the metabolic syndrome [29,
30], and a 12% reduction in the prevalence of the metabolic
syndrome was recently shown in a study [31]. Thus, the
suppressive effect on food intake and appetite observed
previously with this vegetable-oil emulsion in combination
with the obtained effect on body fat mass in this study with
a partial meal replacement therapy could be an important
tool to facilitate compliance to a weight maintenance
program regimen, especially since the test product was well
tolerated. A plausible explanation to the decreased body fat
mass is the effect on resting energy expenditure, which was
found in the previous long-term study, though further
investigations are necessary to conﬁrm the data obtained on
this [20].
Conclusion
A diet using meal replacements containing this stable
emulsion was safe and yielded a signiﬁcantly greater body
fat loss with no differences in weight change after an initial
weight loss compared to the control group. This may
facilitate longer-term compliance with a weight loss pro-
gram and suggests that the program is nutritionally sound if
applied appropriately.
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